LIMN

Liminatus Pharma Inc

2.82

Oct 30 • 3:59 PM ET -0.08 (-2.59%)

2.83

Aftermarket • 7:59 PM ET +0.01 (0.35%)

Healthcare Biotechnology USA Nano NASD

Peers: ALXO APVO KAPA HCWB IMMP PPBT CMPX ADAG CUE XBIT

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	3.79M
Enterprise Value	2.21M
Income	-12.52M
Sales	0.00M
Book/sh	0.27
Cash/sh	2.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	May 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	10.50
P/C	1.25
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.12
Current Ratio	1.12
Debt/Eq	4.80
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-21.48
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -540.05%
Sales past 3/5Y	- -
EPS Y/Y TTM	-107.04%
Sales Y/Y TTM	-
EPS Q/Q	-698.35%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	41.73%
Insider Trans	0.00%
Inst Own	1.41%
Inst Trans	-7.26%
ROA	-471.47%
ROE	-
ROIC	-4165.92%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.98%
SMA50	-22.91%
SMA200	-74.59%
Trades

Shs Outstand	1.12M
Shs Float	0.78M
Short Float	5.08%
Short Ratio	0.18
Short Interest	0.04M
52W High	141.50 -98.01%
52W Low	2.79 1.26%
Volatility	9.36% 8.40%
ATR (14)	0.30
RSI (14)	34.41
Beta	0.74
Rel Volume	0.06
Avg Volume	220.50K
Volume	12,991

Perf Week	-4.08%
Perf Month	-24.80%
Perf Quarter	-50.40%
Perf Half Y	-72.51%
Perf YTD	-90.75%
Perf Year	-96.00%
Perf 3Y	-99.46%
Perf 5Y	-99.42%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	2.89
Price	2.82
Change %	-2.59%

Sep-29-26 09:00AM	Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.43%
Aug-24-26 08:00AM	Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy (GlobeNewswire) -9.50%
Aug-18-26 04:01PM	Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock (GlobeNewswire) -8.06% -14.08%
Aug-13-26 07:15AM	Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +38.16%
Jul-16-26 08:32AM	Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire) +29.00%
04:30PM	Loading…
Jun-30-26 04:30PM	Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline (GlobeNewswire)
Jun-03-26 08:30AM	Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds (GlobeNewswire) -22.21%
May-21-26 08:28PM	Liminatus Pharma Announces Nasdaq Delisting Notification (GlobeNewswire) +30.99% -31.14%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press)
Mar-17-26 08:08AM	Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire)
Feb-17-26 08:44AM	Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -31.86%
Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
08:31AM	Loading…
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.

L.L.M.Mr. Chris Kim J.D.

Chief Financial OfficerMr. Scott Dam

Chief Technology Officer & Member of Scientific Advisory BoardDr. Beom Kyu Choi

Chief Science Officer & Member of Scientific Advisory BoardDr. Byong Chul Yoo Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your Finviz experience